Core Laboratories Inc DE

For the period ended Jun 30, 2024. Filed Jul 25, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Jul 25, 2024

CLB$9.03+2.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets at June 30, 2024 (Unaudited) and December 31, 2023

CONSOLIDATED BALANCE SHEETS

	June 30,2024	December 31,2023
(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$17,695	$15,120
Accounts receivable, net of allowance for credit losses of $2,690 and $2,280 at 2024 and 2023, respectively	115,644	109,352
Inventories	69,898	71,702
Prepaid expenses	9,863	8,153
Income taxes receivable	15,087	13,716
Other current assets	5,341	5,093
TOTAL CURRENT ASSETS	233,528	223,136
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $317,654 and $315,796 at 2024 and 2023, respectively	98,510	99,626
RIGHT OF USE ASSETS	55,689	53,842
INTANGIBLES, net of accumulated amortization and impairment of $19,078 and $18,825 at 2024 and 2023, respectively	6,674	6,926
GOODWILL	99,445	99,445
DEFERRED TAX ASSETS, net	70,531	69,201
OTHER ASSETS	33,422	34,219
TOTAL ASSETS	$597,799	$586,395
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$36,863	$33,506
Accrued payroll and related costs	21,972	18,791
Taxes other than payroll and income	4,957	5,939
Unearned revenues	5,500	4,755
Operating lease liabilities	11,045	10,175
Income taxes payable	8,240	7,280
Other current liabilities	9,021	7,651
TOTAL CURRENT LIABILITIES	97,598	88,097
LONG-TERM DEBT, net	147,621	163,134
LONG-TERM OPERATING LEASE LIABILITIES	42,616	42,076
DEFERRED COMPENSATION	30,678	30,544
DEFERRED TAX LIABILITIES, net	13,250	12,697
OTHER LONG-TERM LIABILITIES	20,342	20,040
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding	—	—
Common stock, 200,000,000 shares authorized, $0.01 par value, 46,938,557 issued and 46,912,695 outstanding at 2024; 46,938,557 issued and 46,856,536 outstanding at 2023	469	469
Additional paid-in capital	113,479	110,011
Retained earnings	132,070	120,756
Accumulated other comprehensive income (loss)	(5,309)	(4,972)
Treasury stock (at cost), 25,862 and 82,021 shares at 2024 and 2023, respectively	(435)	(1,449)
Total Core Laboratories Inc. shareholders' equity	240,274	224,815
Non-controlling interest	5,420	4,992
TOTAL EQUITY	245,694	229,807
TOTAL LIABILITIES AND EQUITY	$597,799	$586,395

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.